Business Context and Reporting Period
Company: Novo Nordisk A/S
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2010
Accounting Basis: International Financial Reporting Standards (IFRS)
Currency: Danish Kroner (DKK)
Novo Nordisk is a global healthcare company and a world leader in diabetes care, with additional leading positions in haemophilia, growth hormone therapy, and hormone replacement therapy. The company operates through two segments: Diabetes Care and Biopharmaceuticals. It employs over 30,000 people in 74 countries and markets products in 180 countries.
Key Financial Metrics (2010)
| Metric | 2010 (DKK Millions) | 2009 (DKK Millions) |
|---|---|---|
| Net Sales | 60,776 | 51,078 |
| Operating Profit | 18,891 | 14,933 |
| Net Profit | 14,403 | 10,768 |
| Earnings Per Share (Diluted) | 24.60 | 17.82 |
| Total Assets | 61,402 | 54,742 |
| Net Assets (Equity) | 36,965 | 35,734 |
| Free Cash Flow | 17,013 | 12,332 |
| Cash Flow from Operating Activities | 19,679 | 15,378 |
| Capital Expenditure | 3,300 | 2,600 |
| R&D Costs | 9,600 (15.8% of sales) | 7,900 (15.4% of sales) |
Dividends: Proposed dividend of DKK 10.00 per share for 2010.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased by 19% (DKK 9.7 billion) compared to 2009, driven by volume growth, price increases, and favorable exchange rates.
- Profitability: Operating profit rose by 27% to DKK 18.9 billion, and net profit increased by 34% to DKK 14.4 billion.
- Share Repurchases: The company completed a share repurchase program in 2010, buying back 19.5 million shares for approximately DKK 9.5 billion. Additionally, 20 million treasury shares were canceled in June 2010, reducing total share capital.
- Capital Investment: Capital expenditure increased to DKK 3.3 billion, primarily due to the construction of a new insulin filling facility in Tianjin, China.
- Patent Expirations: Key patents for NovoRapid expired in Japan (Dec 2010) and Europe (Aug 2011). NovoSeven patents expired in the U.S. (Nov 2010) and Japan (2009), though management expects insignificant impact due to product complexity.
Guidance, Outlook, and Risks
Outlook 2011: Management expects to invest approximately DKK 3.5 billion in fixed assets in 2011, continuing the Tianjin facility construction and establishing new production facilities for delivery devices in Denmark and the U.S.
Key Risks and Contingencies:
- Generic Competition: Generic versions of NovoNorm/Prandin were introduced in several European countries in 2010, expected to significantly reduce sales in those markets. In the U.S., a patent challenge regarding Prandin resulted in an adverse court ruling in January 2011, which the company has appealed.
- Regulatory and Pricing: The company faces risks from government-mandated price decreases and reimbursement changes in key markets.
- Foreign Exchange: Significant exposure to USD, JPY, CNY, and GBP fluctuations, as most sales are in foreign currencies while costs are primarily in DKK.
- Product Liability: Exposure to legal proceedings and product liability claims inherent in the pharmaceutical industry.
Investor Verification Checklist
- Patent Cliff Impact: Verify the actual sales impact of generic competition on NovoNorm/Prandin in Europe and the outcome of the U.S. patent litigation.
- China Expansion: Monitor the progress and cost overruns of the new Tianjin insulin facility, a major capital commitment.
- Shareholder Structure: Note that the Novo Nordisk Foundation (via Novo A/S) holds all A shares (approx. 69% of voting rights), providing significant control over corporate governance.
- Currency Sensitivity: Assess the impact of DKK/USD exchange rate fluctuations on future earnings, given the high proportion of sales in foreign currencies.
- Dividend Policy: Confirm the payout ratio remains consistent with peer pharmaceutical companies as stated in management's intent.